4-[(4-piperidin-1-yl)piperidin-1-yl]benzonitrile

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-[(4-piperidin-1-yl)piperidin-1-yl]benzonitrile
• 英文别名: 4[(4-Piperidin-1-yl)piperidin-1-yl]benzonitrile；4-(4-piperidin-1-ylpiperidin-1-yl)benzonitrile
• 化学式: C₁₇H₂₃N₃
• 分子量: 269.39
• InChiKey: HHMBFPWAMKNJRW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  30.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-[(4-piperidin-1-yl)piperidin-1-yl]benzonitrile 在 盐酸 、 水 作用下， 反应 3.0h， 以92%的产率得到4-[(4-piperidin-1-yl)piperidin-1-yl]benzoic acid hydrochloride
  参考文献：
  名称：

  PIPERIDINE DERIVATIVES

  摘要：

  公开号：

  EP1669350B1
• 作为产物：
  描述：

  4-哌啶基哌啶 、 对氟苯腈 在 potassium carbonate 作用下， 以 二甲基亚砜 为溶剂， 反应 3.0h， 以81%的产率得到4-[(4-piperidin-1-yl)piperidin-1-yl]benzonitrile
  参考文献：
  名称：

  PIPERIDINE DERIVATIVES

  摘要：

  公开号：

  EP1669350B1

文献信息

• [EN] CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY<br/>[FR] HEXAPEPTIDES CYCLIQUES A ACTIVITE ANTIBIOTIQUE
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：WO1996011210A1

  公开（公告）日：1996-04-18

  (EN) This invention relates to new polypeptide compounds represented by formula (I), wherein R1 is as defined in the description and pharmaceutically acceptable salt thereof which have antimicrobial activities (especially, antifungal activities), inhibitory activity on $g(b)-1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for the prophylactic and/or therapeutic treatment of infectious diseases including $i(Pneumocystis carinii) infection (e.g. $i(Pneumocystis carinii) pneumonia) in a human being or an animal.(FR) L'invention porte sur de nouveaux composés de polypeptides représentés par la formule (I) dans laquelle R1 est tel que défini dans la description, ainsi que sur leurs sels pharmacocompatibles qui présentent des activités antimicrobiennes (et spécialement antifongiques), des activités inhibitrices de la $g(b)-1, 3-glucan synthase, sur leur procédé de préparation des préparations pharmaceutiques en contenant, et sur une méthode de traitement prophylactique et/ou thérapeutique de maladies infectieuses dont celles dues au $i(Pneumocystis carinii) (par exemple la pneumonie à $i(Pneumocystis carinii)) chez l'homme ou l'animal.

  该发明涉及由式(I)表示的新的多肽化合物，其中R1如描述中所定义，并且其药学上可接受的盐具有抗微生物活性（特别是抗真菌活性），对$g(b)-1,3-葡聚糖合酶的抑制活性，以及其制备方法，包含该化合物的药物组合物，以及用于人类或动物的感染性疾病（包括$ i（Pneumocystis carinii）感染，例如$ i（Pneumocystis carinii）肺炎）的预防和/或治疗方法。
• Novel piperidine derivative
  申请人：Ohtake Norikazu

  公开号：US20070105901A1

  公开（公告）日：2007-05-10

  Provided are a histamine-H3 receptor antagonist; and a preventive and/or a remedy for metabolic system diseases such as obesity, diabetes, hormone secretion disorder, hyperlipemia, gout, fatty liver, circulatory system diseases, for example, stenocardia, acute/congestive cardiac insufficiency, cardiac infarction, coronary arteriosclerosis, hypertension, nephropathy, sleep disorder and various diseases accompanied by sleep disorder such as idiopathic hypersomnia, repetitive hypersomnia, true hypersomnia, narcolepsy, sleep periodic acromotion disorder, sleep apnea syndrome, circadian rhythm disorder, chronic fatigue syndrome, REM sleep disorder, senile insomnia, night worker sleep insanitation, idiopathic insomnia, repetitive insomnia, true insomnia, electrolyte metabolism disorder, and central and peripheral nervous system diseases such as bulimia, emotional disorder, melancholia, anxiety, epilepsy, delirium, dementia, shinzophrenia, attention deficit/hyperactivity disorder, memory disorder, Alzheimer's disease, Parkinson's disease, sleep disorder, recognition disorder, motion disorder, paresthesia, dysosmia, epilepsy, morphine resistance, narcotic dependency, alcoholic dependency. The histamine-H3 receptor antagonist comprises a piperidine derivative compound of formula (I) [wherein X 1 and X 2 independently represent a nitrogen atom or CH; Y represents a specific group; X 3 represents O s —(CH 2 ) m ; R 1 and R 2 independently represent a hydrogen atom, a halogen atom, a linear or branched lower alkyl group, a lower alkoxy group, or an acetyl group substituted with 2 or 3 fluorine atoms; s is 0 or 1; and m is an integer to make (m+s) 0 or from 1 to 4], or its pharmaceutically-acceptable salt.

  本发明提供了一种组胺H3受体拮抗剂；以及预防和/或治疗代谢系统疾病，例如肥胖症、糖尿病、激素分泌障碍、高脂血症、痛风、脂肪肝、循环系统疾病，例如心绞痛、急性/充血性心力衰竭、心肌梗塞、冠状动脉硬化、高血压、肾病、睡眠障碍以及伴随着睡眠障碍的各种疾病，例如特发性嗜睡症、反复性嗜睡症、真性嗜睡症、嗜睡症、睡眠周期性运动障碍、睡眠呼吸暂停综合征、昼夜节律障碍、慢性疲劳综合征、REM睡眠障碍、老年失眠、夜班工人睡眠不卫生、特发性失眠、反复性失眠、真性失眠、电解质代谢障碍，以及中枢和外周神经系统疾病，例如贪食症、情绪障碍、忧郁症、焦虑症、癫痫、谵妄、痴呆、精神分裂症、注意力缺陷/多动障碍、记忆障碍、阿尔茨海默病、帕金森病、睡眠障碍、认知障碍、运动障碍、感觉异常、嗅觉障碍、癫痫、吗啡耐受、麻醉剂依赖、酒精依赖等的预防和/或治疗剂。该组胺H3受体拮抗剂包括式（I）的哌啶衍生物化合物[其中X1和X2独立地表示氮原子或CH；Y表示特定基团；X3表示Os—（CH2）m；R1和R2独立地表示氢原子、卤素原子、线性或支链低碳基、低碳氧基或2或3个氟原子取代的乙酰基；s为0或1；m是一个使（m+s）为0或1至4的整数]或其药学上可接受的盐。
• NOVEL PIPERIDINE DERIVATIVE
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP1669350A1

  公开（公告）日：2006-06-14

  Provided are a histamine-H3 receptor antagonist; and a preventive and/or a remedy for metabolic system diseases such as obesity, diabetes, hormone secretion disorder, hyperlipemia, gout, fatty liver; circulatory system diseases, for example, stenocardia, acute/congestive cardiac insufficiency, cardiac infarction, coronary arteriosclerosis, hypertension, nephropathy, sleep disorder and various diseases accompanied by sleep disorder such as idiopathic hypersomnnia, repetitive hypetsomnnia, true hypersomnnia, narcolepsy, sleep periodic acromotion disorder, sleep apnea syndrome, circadian rhythm disorder, chronic fatigue syndrome, REM sleep disorder, senile insomnia, night worker sleep insanitation, idiopathic imsomnia, repetitive insomnia, true insomnia, electrolyte metabolism disorder; and central and peripheral nervous system diseases such as bulimia, emotional disorder, melancholia, anxiety, epilepsy, delirium, dementia, shinzophrenia, attention deficit/hyperactivity disorder, memory disorder, Alzheimer's disease, Parkinson's disease, sleep disorder, recognition disorder, motion disorder, paresthesia, dysosmia, epilepsy, morphine resistance, narcotic dependency, alcoholic dependency. The histamine-H3 receptor antagonist comprises a piperidine derivative compound of formula (I) [wherein X1 and X2 independently represent a nitrogen atom or CH; Y represents a specific goup; X3 represents Os-(CH2)m; R1 and R2 independently represent a hydrogen atom, a halogen atom, a linear or branched lower alkyl group, a lower alkoxy group, or an acetyl group substitued with 2 or 3 fluorine atoms; s is 0 or 1; and m is an integer to make (m+s) 0 or from 1 to 4], or its pharmaceutically-acceptable salt.

  本发明提供了一种组胺-H3 受体拮抗剂；以及一种预防和/或治疗代谢系统疾病的药物，例如肥胖症、糖尿病、激素分泌紊乱、高脂血症、痛风、脂肪肝；循环系统疾病，如心血管狭窄、急性/充血性心功能不全、心肌梗塞、冠状动脉硬化、高血压、肾病、睡眠障碍和伴有睡眠障碍的各种疾病，如特发性嗜睡症、重复性嗜睡症、真性嗜睡症、嗜睡症、睡眠周期性运动障碍、睡眠呼吸暂停综合征、昼夜节律紊乱、慢性疲劳综合征、快速眼动睡眠障碍、老年性失眠症、夜班工人睡眠失调症、特发性失眠症、重复性失眠症、真性失眠症、电解质代谢紊乱；以及中枢和周围神经系统疾病，如贪食症、情感障碍、忧郁症、焦虑症、癫痫、谵妄、痴呆、新精神分裂症、注意力缺陷/多动障碍、记忆障碍、阿尔茨海默病、帕金森病、睡眠障碍、识别障碍、运动障碍、麻痹、嗅觉障碍、癫痫、吗啡抵抗、麻醉品依赖、酒精依赖。组胺-H3 受体拮抗剂包括式（I）的哌啶衍生物化合物[其中 X1 和 X2 独立地代表氮原子或 CH；Y 代表特定基团；X3 代表 Os-(CH2)m；R1和R2独立地代表氢原子、卤素原子、直链或支链低级烷基、低级烷氧基或被2或3个氟原子取代的乙酰基；s为0或1；m为整数，使(m+s)为0或1至4]，或其药学上可接受的盐。
• CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0788511B1

  公开（公告）日：2002-12-11
• US6107458A
  申请人：——

  公开号：US6107458A

  公开（公告）日：2000-08-22